Article
15 Jan 2026
Year In Review: Big Deals Of 2025
RANKINGS
This author falls within the Top 20% for their listed topics and industry categories. Based on Mondaq users readership, this author is ranked as VERY POPULAR in United States
AUTHORS CONTENT
Article
11 Nov 2025
Samsung Biologics Completes Spin-Off And Launches Samsung Epis Holdings
Article
01 Aug 2025
Biocon Regulatory Approval Updates In The U.S. And Europe: Insulin Aspart And Denosumab
Article
07 Jul 2025
Amgen Files BPCIA Complaints Against Biocon, Shanghai Henlius/Organon And Hikma/Gideon Richter Regarding Denosumab Biosimilars
Article
24 Mar 2025
PTAB's Reversal Sheds Light On Quantum Computing Patents
Article
13 Nov 2024
Life Sciences M&A Trends For 2023 And 2024 (Through End Of Q3) In Greater China
Article
12 Nov 2024
FDA Accepts BLA For Shanghai Henlius Biotech's And Organon's HLX14, A Denosumab Biosimilar
Article
14 Oct 2024
PTAB Institutes Eight More IPRs Filed By Merck On Johns Hopkins Pembrolizumab Patents
Article
07 Oct 2024
Express Scripts Sues FTC Over Report On Pharmacy Benefit Management Industry
Article
19 Mar 2024
Major Life Sciences Licensing Deal Trends In China In 2023
Article
26 Jan 2024
Year In Review: Top Legal Developments Of 2023
Article
04 Dec 2023
Unlocking AI's Power To Multiply Manufacturing Productivity
Article
30 Nov 2023
Regeneron Sues Samsung Bioepis For Proposed Biosimilar Of EYLEA In West Virginia District Court
Article
22 Nov 2023
UK Authorizes World-First Gene Therapy From Vertex And CRISPR Therapeutics For Blood Disorders
Article
19 Oct 2023
Meitheal Announces Exclusive Commercial Licensing Agreement For Insulin Biosimilars In The US
Article
18 Sep 2023
Generic And Biosimilar Drugs Save $408B For America's Patients And Healthcare System In 2022
Article
11 Jul 2023
HUMIRA (adalimumab) Biosimilar Launches
Article
09 Jun 2023
Updates On Recent Foreign Approvals And Launches
Article
02 Jun 2023
Alvotech And Advanz Pharma Extend Partnership To Commercialize Five Proposed Biosimilars In Europe
Article
04 May 2023
Bristol-Myers Squibb Files Patent Infringement Complaint Against AstraZeneca Regarding Anti-PD-L1 Antibody Product
